M&A insightsNovember 4, 2025

Sector Spotlight Series: Biotech

The biotech sector faces challenges with policy shifts and reduced government research funding in 2025.
Significant acquisitions in the biotech industry include Johnson & Johnson's $14.6B deal and Sanofi's $9.5B deal.
The global biopharma capacity is estimated at $1.5 trillion.
A patent cliff is affecting nearly 190 drugs with a revenue impact of $200 billion.
Despite challenges, M&A activity in biotech is increasing with interest in mid- to late-stage opportunities.

Biotech & Biopharma M&A: Resilience Amid Uncertainty

Welcome back to Datasite’s Sector Spotlight Series, where we explore key trends shaping M&A markets across industries. In this edition, Rachel Barreto, Senior Regional Director at Datasite, shares insights into the biotech and biopharma sector, a space defined by its mission to improve lives through relentless innovation.

Unlike tech, where unicorns chase billion-dollar valuations, biotech reinvests every cent into research and development. The goal isn’t a windfall, it’s the next breakthrough in science and healthcare.

2025: A Challenging Start

The first half of the year has brought significant uncertainty. Policy shifts, including drug pricing pressures and regulatory reforms, have complicated the landscape. Early-stage companies are struggling to raise funds, and cuts to government-backed research have added to the strain.

Yet, the sector remains resilient.

M&A Activity on the Rise

Despite headwinds, M&A momentum is building. Major deals like Johnson & Johnson’s $14.6B acquisition of Intra-Cellular Therapies, Sanofi’s $9.5B purchase of Blueprint Medicines, and Merck’s $10B acquisition of Verona Pharma signal strong investor appetite. With an estimated $1.5 trillion in global biopharma capacity, there’s room for more.

Patent Expirations Driving Demand

A looming patent cliff, impacting nearly 190 drugs and $200 billion in revenue has pharma giants seeking replacement therapies. While early-stage assets often yield lower ROI, there’s still strong interest in mid- to late-stage opportunities. Tools like Datasite Pipeline help investors and acquirers stay organized in this competitive space.

Looking Ahead

As IPOs become less viable, companies are exploring alternative exits like M&A, licensing, and partnerships. The long-term impact of reduced research funding is real, but so is the sector’s adaptability. AI-driven innovation, shorter product lifecycles, and global disruptions will shape the future but biotech will endure and evolve.

Watch the full segment below: